X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES PIRAMAL ENTERPRISES SUVEN LIFESCIENCES/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 22.0 9.5 232.0% View Chart
P/BV x 4.1 1.7 239.3% View Chart
Dividend Yield % 0.6 0.9 58.5%  

Financials

 SUVEN LIFESCIENCES   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
PIRAMAL ENTERPRISES
Mar-18
SUVEN LIFESCIENCES/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs2513,083 8.1%   
Low Rs1551,902 8.1%   
Sales per share (Unadj.) Rs49.1589.7 8.3%  
Earnings per share (Unadj.) Rs9.7284.0 3.4%  
Cash flow per share (Unadj.) Rs11.4310.5 3.7%  
Dividends per share (Unadj.) Rs1.5025.00 6.0%  
Dividend yield (eoy) %0.71.0 73.7%  
Book value per share (Unadj.) Rs60.31,467.0 4.1%  
Shares outstanding (eoy) m127.28180.27 70.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.14.2 97.7%   
Avg P/E ratio x20.98.8 237.9%  
P/CF ratio (eoy) x17.88.0 221.9%  
Price / Book Value ratio x3.41.7 198.1%  
Dividend payout %15.48.8 175.4%   
Avg Mkt Cap Rs m25,825449,332 5.7%   
No. of employees `0001.16.8 15.7%   
Total wages/salary Rs m61319,881 3.1%   
Avg. sales/employee Rs Th5,832.615,535.6 37.5%   
Avg. wages/employee Rs Th571.52,905.4 19.7%   
Avg. net profit/employee Rs Th1,153.87,482.5 15.4%   
INCOME DATA
Net Sales Rs m6,253106,310 5.9%  
Other income Rs m2332,595 9.0%   
Total revenues Rs m6,485108,906 6.0%   
Gross profit Rs m1,98251,599 3.8%  
Depreciation Rs m2134,773 4.5%   
Interest Rs m4629,783 0.2%   
Profit before tax Rs m1,95519,638 10.0%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m718-28,764 -2.5%   
Profit after tax Rs m1,23751,203 2.4%  
Gross profit margin %31.748.5 65.3%  
Effective tax rate %36.7-146.5 -25.1%   
Net profit margin %19.848.2 41.1%  
BALANCE SHEET DATA
Current assets Rs m5,622118,154 4.8%   
Current liabilities Rs m1,168462,260 0.3%   
Net working cap to sales %71.2-323.7 -22.0%  
Current ratio x4.80.3 1,883.9%  
Inventory Days Days8127 306.4%  
Debtors Days Days3647 77.2%  
Net fixed assets Rs m3,325113,727 2.9%   
Share capital Rs m127361 35.3%   
"Free" reserves Rs m7,547264,093 2.9%   
Net worth Rs m7,674264,454 2.9%   
Long term debt Rs m14242,206 0.0%   
Total assets Rs m9,135726,834 1.3%  
Interest coverage x43.21.7 2,605.0%   
Debt to equity ratio x00.9 0.2%  
Sales to assets ratio x0.70.1 467.9%   
Return on assets %14.011.1 126.1%  
Return on equity %16.119.4 83.2%  
Return on capital %26.010.3 252.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,06615,110 33.5%   
Fx outflow Rs m2,0014,298 46.6%   
Net fx Rs m3,06510,813 28.3%   
CASH FLOW
From Operations Rs m699-159,666 -0.4%  
From Investments Rs m-6-17,677 0.0%  
From Financial Activity Rs m-577186,503 -0.3%  
Net Cashflow Rs m1169,364 1.2%  

Share Holding

Indian Promoters % 63.4 52.9 119.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 4.0 -  
FIIs % 0.0 26.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 16.5 221.2%  
Shareholders   37,287 93,274 40.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  AJANTA PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY19); Net Profit Up 21.8% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 21.8% YoY). Sales on the other hand came in at Rs 35 bn (up 22.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Apr 18, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - MERCK COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS